Abstract
Inflammatory bowel disease, especially Crohn disease, had increased in the last five decades. We analyzed all the patients of our unit diagnosed with the disease between 2001-2012 but we just considered the patients who respected the Porto criteria to define IBD at presentation. We diagnosed 51 children and adolescents with the disease. Crohn disease was responsible for 62.7% of cases, ulcerative colitis for 31.4% and indeterminate colitis for 5.9%. Considering the 4 different periods of time (2001-2003/2004-2006/2007-2009 and 2010-2012), we observed and increase in the number of cases, but a decrease in the time from onset of symptoms to diagnosis. Our medical approach with tumor necrosis factor antagonists was reserved for severe disease cases and to spare patients from adverse effects of purine analogues and corticosteroids. Mucosal healing and remission of the disease was achieved in all of the patients under biologic therapy and no serious or life-threating event was reported with their use.
Highlights
Inflammatory Bowel Disease (IBD) represents a heterogeneous group of chronic diseases, diagnosed before the age of 20 years in 25% to 30% of cases [1,2,3]
Crohn Disease (CD) was responsible for 62.7% (n=32) of cases, Ulcerative Colitis (UC) for 31.4% (n=16) and Indeterminate Colitis (IC) for 5.9% (n=3) (Table 1)
The periods of times between 2007-2009 and 2010-2012 were the periods with more diagnosed cases, but they corresponded to the periods when the time from onset of symptoms to diagnosis was shorter, even if this difference was not statistically significant (ρ>0.01); the gastroenterology unit, had a relatively constant mean number of consultations every 2-3 months to achieve diagnosis (Table 1)
Summary
Inflammatory Bowel Disease (IBD) represents a heterogeneous group of chronic diseases, diagnosed before the age of 20 years in 25% to 30% of cases [1,2,3]. Recent epidemiological studies have shown an increasing incidence of IBD in the last five decades. Crohn Disease (CD), more than Ulcerative Colitis (UC) and Indeterminate Colitis (IC), is the major responsible for this upraising of pediatric cases [3,4,5,6]. The use of biologic therapy (tumor necrosis factor antagonists) is becoming a safe and more advocated strategy to manage pediatric IBD [7,8,9,10,11,12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
